Bayer HealthCare and Cardinal Health have signed a 15-year agreement for the contract manufacturing of Xofigo. As part of the agreement, Cardinal Health will build a state-of-the art, 64,000 square foot facility in Indianapolis, which will be dedicated exclusively to the manufacturing of Xofigo.
POZEN said that their investigational drug candidates YOSPRALA™ 81/40 and 325/40 have received a...
Earlier this week, President Barack Obama signed into law a little piece of legislation that may...
Low migration labels are ideal for use in plastic containers, which are increasingly being used in lieu of glass in primary pharmaceutical packaging. Utilizing qualified adhesive systems, materials and inks, specialty labels can be customized to suit a wide range of plastic container packaging applications.
The ALR-1 features a CA1 back pressure regulator mounted onto it like the previously introduced ULR-1 and PTR-1 valves. Instead of the inlet pressure feeding into the cover dome, an auxiliary air supply, such as air from a compressor, will feed the cover dome.
Biothera has joined AstraZeneca, Astex Pharmaceuticals, Eli Lilly and Company, MedImmune and Verastem as the latest pharmaceutical partner in Cancer Research UK's Combinations Alliance.
The Watertown, Massachusetts, company said eravacycline proved to be not inferior to a competing drug, ertapenem, and patients taking it had no serious, drug-related side effects, according to early results from the study.
Agenus and its partner GlaxoSmithKline have reported that the ZOE-50 Phase III study met its primary endpoint. Analysis of the primary endpoint showed that HZ/su reduced the risk of shingles by 97.2% in adults aged 50 years and older compared to placebo.
Pfizer has announced top-line results from a double-blind Phase III study evaluating pregabalin controlled-release (CR) formulation in adult patients with postherapeutic neuralgia (pain after shingles or PHN).
The grants awarded by the Colorado Board of Health will go to studies on whether marijuana helps treat epilepsy, brain tumors, Parkinson's disease and post-traumatic stress disorder. Some of the studies still need federal approval.
Health officials are celebrating some important victories in 2014, and Time magazine even named Ebola fighters the persons of the year. Nevertheless, this was a black-eye year for public health.
AstraZeneca today announced that the European Commission has granted Marketing Authorization for Lynparza™ capsules as the first therapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cance.
Federal prosecutors say the owner and president of a dietary supplement company has admitted his role in the sale of diluted and adulterated dietary ingredients and supplements sold by his company.
A federal judge dismissed a lawsuit by 1,300 former players against the NFL, writing that the collective bargaining agreement between the league and the union was the appropriate forum to resolve claims that teams damaged the players' by routinely dispensing painkillers.
Researchers are reporting another disappointment for efforts to cure infection with the AIDS virus. Six patients given blood-cell transplants similar to one that cured a man known as "the Berlin patient" have failed, and all six patients died.
Merck has acquired, through a subsidiary, OncoEthix, a Swiss-based privately held biotechnology company specializing in oncology drug development. Through the acquisition, Merck has gained an investigational, novel oral BET inhibitor, OTX015, which is currently in Phase 1b studies for the treatment of hematological malignancies and advanced solid tumors.
United Therapeutics Corporation has announced two senior executive promotions as well as changes to Martine Rothblatt, Ph.D's compensation program.
Researchers in the Netherlands found that mechanically removing a clot in addition to using a clot-busting medicine lowered the risk that a stroke sufferer would end up severely disabled.